15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering ResMed Inc, 5 rate it Buy or better, 7 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $220.00 to $325.00, a moderate spread. The average target of $256.09 sits 23% above the current $209.01. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.84 next quarter toward $12.08 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Moderate Buy
Strong Buy00%
Buy542%
Hold758%
Sell00%
Strong Sell00%
Based on 12 analysts giving stock ratings to ResMed Inc.
As of Jul, 5 of 12 firms rate RMD a Buy (7 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RMD EPS & revenue forecast
EPS · NEXT QUARTER
$2.84
Range $2.81 – $2.89 · 4 analysts · +11% YoY
Next period, 4 analysts expect ResMed Inc to earn $2.84 a share (range $2.81 – $2.89), versus $2.55 a year earlier. , growing to $12.08 the year after.
REVENUE · NEXT QUARTER
$1.4B
Range $1.4B – $1.5B · 4 analysts · +6% YoY
Revenue is expected to reach $1.4B (range $1.4B – $1.5B), +6.3% year-over-year., rising to $6.0B next year.
Top analysts covering ResMed Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RMD.
#1
Jonathan Block
Stifel · Rank #172
Hold
$235.00+12.4% to target
Overall win rate
42%
+ Follow
#2
Justin Patterson
Keybanc · Rank #329
Buy
$266.00+27.3% to target
Overall win rate
26%
+ Follow
#3
CW
Craig Wong-Pan
RBC Capital
Buy
$276.00+32.1% to target
Coverage
—
+ Follow
#4
LS
Laura Sutcliffe
Citigroup
Hold
$235.00+12.4% to target
Coverage
—
+ Follow
#5
Anthony Petrone
Mizuho
Buy
$220.00+5.3% to target
Coverage
—
+ Follow
RMD stock forecast FAQ
What is RMD's average 12-month price target?+
The 11 analysts with a live target average $256.09 for ResMed Inc over the next 12 months, ranging from a $325.00 high to a $220.00 low.
Is RMD stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 12 analyst ratings, 5 are Buy or Strong Buy, 7 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RMD?+
The Street-high target is $325.00 (UBS), and the Street-low is $220.00 (Mizuho). The average of all 11 active targets is $256.09.
How many Wall Street analysts cover RMD?+
12 analysts have an active rating on ResMed Inc, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering RMD?+
Among analysts who currently cover RMD, Jonathan Block of Stifel has the strongest overall Quantellect track record (Rank #172). Their current call is Hold with a $235.00 target.
What is ResMed Inc's projected EPS for next quarter?+
The consensus estimate is $2.84 per share (range $2.81 – $2.89) across 4 analysts, rising to $12.08 the following year.
How much revenue is ResMed Inc expected to report next quarter?+
Consensus revenue is $1.4B (range $1.4B – $1.5B), growing to $6.0B next year.
Have analysts been upgrading or downgrading RMD lately?+
As of Jul, 5 of 12 firms rate RMD a Buy (7 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RMD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
